



# Biotech Daily

Thursday August 26, 2021

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: PATRYS UP 22%; STARPHARMA DOWN 5.5%**
- \* **COMPUMEDICS REVENUE UP 2% TO \$36m, LOSS TO \$1m PROFIT**
- \* **POLYNOVO REVENUE UP 32% TO \$29m, LOSS UP 10% TO \$5m**
- \* **KAZIA REVENUE \$15m, LOSS DOWN 32% TO \$8m**
- \* **CONTROL BIONICS REVENUE UP 28% TO \$4m, LOSS UP 253% TO \$3.5m**
- \* **RHINOMED REVENUE UP 9% TO \$3.9m, LOSS UP 18% TO \$8m**
- \* **STARPHARMA REVENUE DOWN 67% TO \$2m, LOSS UP 34% TO \$19.7m**
- \* **DORSAVI REVENUE DOWN 7% TO \$1.8m, LOSS DOWN 73% TO \$2m**
- \* **LBT REVENUE DOWN 5% TO \$1.4m, LOSS UP 28% TO \$7m**
- \* **ONCOLOGY ONE, CHILDREN'S CANCER INSTITUTE WORK ON SOLID TUMORS**
- \* **DASH LAUNCHES ACRUX GENERIC TESTOSTERONE IN THE US**
- \* **NOVA EYE PAYS \$2.8m FOR US GLAUCOMA PATENTS**
- \* **USPTO ALLOWS CYNATA CYMERUS STEM CELL PATENT**
- \* **SUDA APPOINTS DR REUBEN BENJAMIN ADVISOR**

## MARKET REPORT

The Australian stock market fell 0.54 percent on Thursday August 26, 2021, with the ASX200 down 40.7 points to 7,491.2 points. Fifteen of the Biotech Daily Top 40 stocks were up, 17 fell and eight traded unchanged.

Patrys was the best on no news, up 0.8 cents or 22.2 percent to 4.4 cents, with 33 million shares traded. Prescient climbed 7.9 percent; Immutep and Kazia improved more than six percent; Imugene, LBT and Resonance were up more than four percent; Clinuvel and Opthea climbed more than three percent; Cynata and Optiscan rose more than two percent; Dimerix, Medical Developments and Proteomics were up one percent or more; with Nanosonics and Resmed up by less than one percent.

Starpharma led the falls, down seven cents or 5.5 percent to \$1.20, with 761,767 shares traded. Actinogen, Oncosil and Polynovo fell four percent or more; Genetic Signatures, Impedimed, Telix and Uscom lost three percent or more; Alterity, Compumedics and Mesoblast shed more than two percent; CSL, Nova Eye, Orthocell, Paradigm and Pro Medicus were down one percent or more; with Avita, Cochlear and Neuren down by less than one percent.

## COMPUMEDICS

Compumedics says revenue for the year to June 30, 2021, was up 1.9 percent to \$35,740,000 with net loss after tax turned to a profit of \$998,000.

Compumedics said revenue was from sales of its sleep diagnostic systems, electro-encephalogram systems, brain monitoring systems, ultrasonic blood-flow systems, supplies and technical service and support.

The company said it had \$10,400,000 in revenue from the US, \$14,085,000 from Australia and the Asia Pacific and \$35,740,000 from Europe.

Last year, Compumedics said that sleep and neurological diagnostic and monitoring service providers had been suspended (BD: Aug 31, 2020).

Today, Compumedics said it was continuing to pursue sleep and other neurological applications in the larger markets and more recently the potential application of the Somfit device as multi-modal vital signs monitor for potential Covid-19 application.

The company said sales in China declined four percent and its Japan-based neurological business was down 26 percent due to the on-going issues with the Covid-19 pandemic.

The company said that last year's 3.3 cents diluted loss per share turned to a diluted earnings per share of 0.6 cents, with net tangible asset backing per share down 5.8 percent to 9.7 cents, and it had cash and cash equivalents of \$6,770,000 at June 30, 2021 compared to \$6,412,000 at June 30, 2020.

Compumedics fell one cent or 2.3 percent to 43 cents.

## POLYNOVO

Polynovo says revenue for the year to June 30, 2021 was up 32.0 percent to \$29,339,324 with net loss after tax up 9.8 percent to \$4,605,032.

Polynovo said revenue was from its Novosorb technology for biodegradable medical devices and included \$24,323,537 from the US, \$3,243,920 from Australia and New Zealand, \$1,590,467 from the rest of the world, \$1,103 in interest and \$180,297 in other income.

The company said that revenue to the US Biomedical Advanced Research and Development Authority (BARDA) was \$3,650,065.

The company said diluted loss per share was up 9.5 percent to 0.69 cents, with net tangible asset backing per share unchanged at three cents, and it had cash and cash equivalents of \$7,688,554 at June 30, 2021 compared to \$11,647,701 at June 30, 2020.

Polynovo fell nine cents or 4.2 percent to \$2.04 with 4.9 million shares traded.

## KAZIA THERAPEUTICS

Kazia says licencing revenue for the year to June 30, 2021 was \$15,182,711 with a net loss after tax down 32.4 percent to \$8,421,960.

Last month, Kazia chief executive officer Dr James Garner told Biotech Daily that the company's revenue was derived primarily from a Simcere Pharmaceutical Group payment, with an additional \$4 million from the sale of Cantrixil to Uppsala, Sweden's Oasmia Pharmaceutical China (BD: May 30, Jul 30, 2021).

Today, the company said its diluted loss per share was down 58.1 percent to 7.17 cents, net tangible assets were up 563.5 percent to 12.01 cents and it had cash and cash equivalents of \$27,586,760 at June 30, 2021 compared to \$8,764,044 at June 30, 2020.

Kazia was up 7.5 cents or six percent to \$1.32.

## CONTROL BIONICS

Control Bionics says revenue for the year to June 30, 2021 was up 28.2 percent to \$3,972,119 with net loss after tax up 253.1 percent to \$3,550,826.

In December, Control Bionics listed on the ASX after raising \$15 million at 60 cents a share to commercialize its Neuronode technology for conversion of thoughts to computerized actions (BD: Dec 8, 2020).

Today, the company said its diluted loss per share was down 44.5 percent to 5.66 cents, compared to the previous year.

Control Bionics said that its net tangible asset backing per share was unchanged at 0.16 cents.

The company said that it had cash and cash equivalents of \$12,331,109 at June 30, 2021 compared to 1,428,405 at June 30, 2020.

Control Bionics fell two cents or 2.8 percent to 70 cents.

## RHINOMED

Rhinomed says revenue for the year to June 30, 2021, was up 9.2 percent to \$3,894,908 with net loss after tax up 18.9 percent to \$8,638,926.

Rhinomed said that despite the global pandemic, units of its Mute anti-snoring, Turbine sports and Pronto inhaler nasal dilators shipped increased by 10 percent compared to the prior year.

The company said as a direct result of the lockdowns across a number of markets, retail sales fell due to the decrease in foot traffic, but revenue from online sales offset that decline.

The company said that diluted loss per share was down 23.3 percent to 3.4 cents, with net tangible asset backing per share down 70 percent to 1.02 cents.

Rhinomed said that it had cash and cash equivalents of \$2,339,616 at June 30, 2021 compared to \$7,757,474 at June 30, 2020.

Rhinomed fell 2.5 cents or 7.25 percent to 32 cents.

## STARPHARMA

Starpharma says revenue for the year to June 30, 2021 was down 67.2 percent to \$2,151,000 with net loss after tax up 34.4 percent to \$19,732,000.

Starpharma said that the total revenue from contracts with customers was down 70.2 percent to \$1,798,000, which was predominantly product sales and royalties on Viraleze and Vivagel products.

The company said that revenue from contracts in the prior year included \$4,339,000 on Astrazeneca triggering a non-recurring \$US3 million (\$A4.13 million) milestone for the first dose of AZD0466 administered in the phase I trial of its first dendrimer enhanced product (DEP).

The company said its revenue from interest was down 32.5 percent to \$353,000.

Starpharma said diluted loss per share was up 25 percent to five cents, with net tangible asset backing per share up 87.5 percent to 15 cents.

The company said it had cash and cash equivalents of \$60,500,000 at June 20, 2021 compared to \$30,054,000 at June 30, 2020.

Starpharma fell seven cents or 5.5 percent to \$1.20.

## DORSAVI

Dorsavi says revenue for the year to June 30, 2021, was down 7.4 percent to \$1,868,982 with net loss after tax down 73.3 percent to \$2,028,267.

Dorsavi said clinical income from its wearable sensors for patient assessments was up 0.4 percent to \$1,130,045 and workplace income from wearable devices and its Myvisafe product in the US, the UK and Australia was down 17.4 percent to \$738,937.

The company said it experienced resilient top line revenue performance, supported by a “robust” clinical market and strategic transition towards the more reliable recognized recurring revenue model during 2020-'21.

Dorsavi said that diluted loss per share down 80.5 percent to 0.68 cents, with net tangible asset backing per share was up 210 percent to 0.62 cents.

The company said that it had cash and cash equivalents of \$2,796,175 at June 30, 2021 compared to \$1,685,288 at June 30, 2020.

Dorsavi was untraded at 2.2 cents.

## LBT INNOVATIONS

LBT says revenue for the year to June 30, 2021 was down 4.7 percent to \$1,434,000 with net loss after tax up 28.8 percent to \$7,260,000.

LBT said that revenue came from consulting services and other related expenses invoiced to its joint venture company, the Zurich, Switzerland-based Clever Culture Systems, as well as sales of three automated plate assessment system (APAS) Independence instruments.

The company said that said that diluted loss per share was up 4.6 percent to 2.53 cents at June 30, 2021, with net tangible assets per share down 9.7 percent to 4.1 cents.

LBT said that it had cash and cash equivalents of \$9,615,000 at June 30, 2021 compared to \$7,096,000 at June 30, 2020.

LBT was up half a cent or 4.2 percent to 12.5 cents.

## ONCOLOGY ONE PTY LTD

Melbourne's Oncology One says it has partnered with Sydney's Children's Cancer Institute to develop small molecule drugs to treat of childhood solid tumors.

Oncology One said the partnership aimed to treat neuroblastoma, a tumor that forms in the adrenal glands above the kidney, or near the spine, chest, neck, or pelvis.

The company said that with one in 100,000 children developing neuroblastoma, it was “the most prevalent extra-cranial solid tumor in children under five years old”.

Oncology One said it would work with the Children's Cancer Institute's drug discovery initiative, Therapeutic Innovations for Kids (Think), based on research by Prof Tao Liu.

The company said that Prof Liu identified a protein target that drove tumor growth and was a regulator of gene expression in neuroblastoma and the collaboration would seek to identify small molecule compounds that inhibited the tumor-driving biological activity of the target, by screening hundreds of thousands of compounds.

Oncology One chief executive officer Dr Joanne Boag said that, if successful, “further work will be needed to develop these compounds towards a lead candidate and then a clinical candidate that would become an investigational new drug and enter clinical trials.

Oncology One is a private company.

## ACRUX

Acrux says that Dash Pharmaceuticals has begun US marketing of its generic testosterone topical solution.

Earlier this year, Acrux said the US Food and Drug Administration had approved its generic version of Perrigo's 30mg/1.5mL testosterone topical solution (BD: Jan 17, 2021).

Today, Acrux managing-director Michael Kotsanis told Biotech Daily the product was "a generic of Perrigo's Testosterone Topical Solution ... in effect a generic of Axiron".

In 2017, Acrux said it and Eli Lilly and Co terminated the Axiron testosterone replacement licence, ending US sales, with Biotech Daily calculating that Eli Lilly received revenue of more than \$US810.8 million (\$A975.5 million) from Axiron sales (BD: Sep 6, 2017).

Mr Kotsanis told Biotech Daily at that time that the FDA required a testosterone replacement trial which would cost "hundreds of millions of dollars" and sales had fallen since July 5, 2017, when generic versions of Axiron appeared on the market.

Today, Acrux said it licenced the product to Dash Pharmaceuticals in October 2020, with an addressable market of \$US20 million a year competing against four marketed generics.

Mr Kotsanis said the generic testosterone was "the first of the pipeline of topical generic products that Acrux has launched".

"It's an important milestone for the company," Mr Kotsanis said.

Acrux was up one cent or 8.3 percent to 13 cents.

## NOVA EYE

Nova Eye says it has paid \$US2 million (\$A2,754,082) and issued 1,736,653 shares to Innovative Glaucoma Solutions for a portfolio of glaucoma treatment patents.

Nova managing-director Tom Spurling said the acquisition supported the company's strategy "to develop a comprehensive portfolio of glaucoma treatment technologies".

"This transaction expands and strengthens our glaucoma surgical device intellectual property portfolio and will facilitate the future introduction of new products and additional indications," Mr Spurling said.

"The future products will address glaucoma patients with mid-stage disease, complementing the Itrack and Molteno3 technologies and equipping our surgeon customers with a comprehensive portfolio of treatment technologies to target all stages of the glaucoma disease process," Mr Spurling said.

Nova Eye said that the Dallas, Texas-based Innovative Glaucoma Solutions LLC was a surgeon-owned company.

Nova Eye fell half a cent or 1.2 percent to 42.5 cents.

## CYNATA THERAPEUTICS

Cynata says the US Patent and Trademark Office has allowed a patent relating to its Cymerus mesenchymal stem cell technology.

Cynata said the patent, titled 'Colony Forming Medium and Use Thereof' was expected to be granted in early November 2021 and would be valid until March 14, 2037.

The company said the patent would extend the intellectual property protection for the Cymerus manufacturing platform and its ability to yield "highly consistent mesenchymal stem cells at scale from a single donation to create therapeutic stem cell products".

Cynata chief executive officer Dr Ross Macdonald said the "award of a US patent is one of the most important achievements for innovative companies such".

Cynata was up 1.5 cents or 2.9 percent to 53.5 cents.

## SUDA PHARMACEUTICALS

Suda says it has appointed Dr Reuben Benjamin to its scientific advisory board for the invariant natural killer T-cell therapy platform.

Suda said Dr Benjamin had an active research group at King's College London focusing on allogeneic CAR-T cells for lymphoid malignancies as well as studying the biology of extramedullary myeloma.

Suda was up half a cent or 11.1 percent to five cents.